49 articles for thisTarget
              
              The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.

Sichuan University
 
Recent Progress in Histone Demethylase Inhibitors.

University of Oxford
 
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.

Kyoto Prefectural University of Medicine
 
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.

University of Oxford
 
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.

Kyoto Prefectural University of Medicine
 
Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.

University of North Carolina at Chapel Hill
 
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.

Kyoto Prefectural University of Medicine
 
Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain.

University of North Carolina Eshelman School of Pharmacy
 
Inhibition of demethylases by GSK-J1/J4.

EpiTherapeutics Aps
 
Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.

Osaka University
 
Pharmacological inhibition of KDM5A for cancer treatment.

Ningbo University
 
From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).

University of S£O Paulo
 
Recent Advances with KDM4 Inhibitors and Potential Applications.

St. Jude Children'S Research Hospital
 
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).

Hangzhou Normal University
 
Discovery of Novel Pyrazole-Based KDM5B Inhibitor 

Zhengzhou University
 
Discovery of a new class of JMJD6 inhibitors and structure-activity relationship study.

Nankai University
 
Discovery of a potent and selective inhibitor of histone lysine demethylase KDM4D.

Nankai University
 
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).

Zhengzhou University
 
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.

Genentech
 
Identification of potent, selective KDM5 inhibitors.

Constellation Pharmaceuticals
 
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Genentech
 
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.

Kyoto Prefectural University of Medicine
 
Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.

Kyoto Prefectural University of Medicine
 
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.

University of Oxford
 
The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.

University of North Carolina
 
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.

The University of Texas M.D. Anderson Cancer Center
 
Structure-based design and discovery of potent and selective KDM5 inhibitors.

Celgene
 
Methyllysine binding domains: Structural insight and small molecule probe development.

University of Connecticut
 
Investigations on small molecule inhibitors targeting the histone H3K4 tri-methyllysine binding PHD-finger of JmjC histone demethylases.

University of Oxford
 
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Genentech
 
Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A.

The University of Texas M.D. Anderson Cancer Center
 
Discovery of pyrazolo[1,5-a]pyrimidine-3-carbonitrile derivatives as a new class of histone lysine demethylase 4D (KDM4D) inhibitors.

Sichuan University
 
INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF TUMOR OR CELL PROLIFERATIVE AND FIBROSIS DISEASES

National Taiwan University
 
Bicycloheptane pyrrolidine orexin receptor agonists

Merck Sharp & Dohme
 
Indole derivatives and their use as protein kinase inhibitors

Respivert
 
Imidazopyrrolidine derivatives and their use in the treatment of disease

Novartis
 
Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors

Zhejiang Dtrm Biopharma
 
Inhibitors of c-fms kinase

Janssen Pharmaceutica
 
Substituted heteroaryl compounds and methods of use

Calitor Sciences
 
Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis.

Philipps-Universität Marburg
 
Roles of phosphate recognition in inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) substrate binding and activation.

Mcgill University
 
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

Almirall
 
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.

Whitehead Institute For Biomedical Research
 
Novel 4-heteroaryl-antipyrines as DPP-IV inhibitors.

Cairo University
 
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Merck Sharp & Dohme
 
In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist.

Whitby Research